Guardant Health (GH) Leerink Global Healthcare Conference 2026 summary

Strategic partnerships and market expansion

• Announced partnership with Quest Diagnostics to broaden Shield test access, leveraging Quest's EMR system and co-promotion through its PCP channel.

• Quest partnership expected to increase Shield test ordering depth and physician education, with co-promotion impact anticipated in the second half of the year.

• Recent guideline updates for colorectal cancer (CRC) now recommend comprehensive profiling in stage 2 and 3, expanding the addressable patient population by 50%-75%.

• Ongoing engagement with health systems and international expansion are considered upside factors not yet included in current guidance.

• ACS guideline recommendation for Shield is anticipated soon, which could further boost accessibility and adoption.

Product innovation and clinical adoption

• Guardant360 continues to see strong growth, driven by increased clinical adoption and repeat testing, with average tests per patient rising from 1.2 to 1.3.

• Liquid biopsy is shifting cancer care from single lifetime tests to multiple tests per therapy line, tracking tumor evolution.

• New drug approvals and updated guidelines are driving earlier and broader use of comprehensive genomic profiling.

• FDA approval for Guardant360 is expected in the second half of the year, consolidating the portfolio and enabling ADLT repricing by early 2027.

• Ongoing R&D and AI-driven improvements, including the MetaSight acquisition, are expected to enhance Shield and other products' performance.

Financial outlook and operational strategy

• Shield revenue guidance set at $160M-$174M for the year, reflecting 130% YoY growth, with upside potential from Quest, DTC campaigns, and health system engagement.

• ASP for Shield is guided at $775 for 2026, with deliberate short-term reduction to drive volume, expected to recover as commercial payer adoption increases.

• Incremental gross profit is being reinvested in DTC campaigns, sales force expansion, and targeted marketing, with OpEx growth focused on sales and marketing.

• Commitment to achieving cash flow breakeven by end of 2027, with potential to accelerate timeline if gross profit improves.

• Sales force ramping from 100 to 300 reps last year, targeting 600-700 by 2028, with productivity improvements expected as reps mature.